Alcyone Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alcyone Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Alcyone Therapeutics: 3 sponsored US clinical trials, 1 recruiting.
Alcyone Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is CLN3, with 1 trials.
Upper-quartile sponsor footprint
Alcyone Therapeutics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419
Gene Therapy for Children With CLN3 Batten Disease
NCT03770572
Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters
NCT02651337
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Alcyone Therapeutics pipeline
1 recruiting of 3 indexed (33% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: CLN3 (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alcyone Therapeutics: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Alcyone Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Alcyone Therapeutics page
3 registered trials is a research-attention snapshot, not an endorsement of Alcyone Therapeutics or any single study.
- 1 of Alcyone Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- CLN3 is the condition Alcyone Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See CLN3 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alcyone Therapeutics pipeline card: 3 registered trials from official public datasets.Report a data error.